mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-18. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
The formation of the ring system involves first alkylation of the anion from thiophenol with dimethylallyl bromide (1) to give the thioether (2). Friedel-Crafts cyclization of the olefin with the equivalent of PPA then gives the thiopyran (3). Acylation with acetyl chloride in the presence of aluminium chloride gives the methyl ketone (4). Reaction of the enolate of that ketone with diethyl chlorophosphate gives the enol phosphate 5 as a transient intermediate. This eliminates diethyl phosphite in the presence of excess base to give the corresponding acetylene 6. The anion from the reaction of the acetylene with base is then used to displace chlorine from Ethyl 6-chloronicotinate (7). This reaction affords the coupling product tazarotene (8).
== Applications == Copurification procedures, such as co-immunoprecipitation, are commonly used to analyze interactions between proteins. Copurification is one method used to map the interactome of living organisms.
=== Side effects === Xylazine overdose is often fatal in humans. Because it is used as a drug adulterant, the symptoms caused by the drugs accompanying xylazine administration vary between individuals. The most common side-effects in humans associated with xylazine administration include bradycardia, respiratory depression, hypotension, transient hypertension secondary to α1-adrenergic receptor stimulation, and other central and hemodynamic changes. Xylazine significantly decreases heart rate in animals that are not pre-medicated with medications that have anticholinergic effects. Symptoms that can occur following overdose are areflexia, asthenia, ataxia, blurred vision, disorientation, dizziness, dysarthria, dysmetria, fainting, hyporeflexia, somnolence, coma, apnea, premature ventricular contraction, tachycardia, miosis, and hyperglycaemia. Rarely, hypotonia, urinary incontinence, and nonspecific electrocardiographic ST segment changes occur. Following a human overdose, symptoms can last for 8–72 hours, varying based on xylazine's combined usage with other drugs.
Director, Yorkshire Arboretum. For services to Tree Health and Plant Conservation. Liam Daniel Hackett. Founder and Chief Executive Officer, Ditch the Label. For services to Young People. Elizabeth Hall. Founder, The Hygiene Bank. For services to Tackling Hygiene Poverty. Penelope Evelyn Hall (Penelope Gravill). Speech and Language Therapist, Aberdeen Royal Infirmary. For services to the Treatment of Skull Base Tumours and Facial Palsies. Zahid Hamid. Lately Member, Peak District National Park Authority. For services to National Parks. Dr. Simon Leslie Hancock. Councillor, Pembrokeshire County Council. For services to the community in Pembrokeshire. Adam Peter Ritchie Handling. Chef, Ambassador of The GREAT Britain and Northern Ireland Campaign. For services to Hospitality and International Trade. Richard Heafield Harris. Fintech Innovator and Entrepreneur, Ensygnia (Onescan). For services to Fintech Innovation and to Global Technological Advancement. Valda Harris (Valda Jackson). Artist. For services to Art. Lesley Ann Hastings. For services to the community in Leeds, West Yorkshire. Philip Hugh Michael Haughton. Founder, Better Food. For services to Sustainable Food Initiatives and to the community in Bristol. Elizabeth Ann Hawkins. For services to Young People and to the community in Wirral, Merseyside. Lauren May Hemp. Footballer. For services to Association Football. Alasdair Cunningham Hendry. Senior Operations Manager, Forestry Commission. For services to Forestry and to Climate Change Mitigation. Alice Maria Hendy. Founder, R;pple Suicide Prevention Charity.
== Therapeutic touch and nursing education == Sokal, in 2006, reported generally accepted estimates of over 80 colleges and universities spread over 70 countries where therapeutic touch is taught, as well as some 80 hospitals in North America where it is practiced. He added that "these figures should be taken with a grain of salt, since both advocates and detractors [...] have an interest in exaggerating its incidence". Owen Hammer and James Underdown of the Independent Investigations Group examined nursing standards in California, where the California Board of Registered Nursing can award registered nurses taking classes in therapeutic touch with continuing education units required for licensure renewal. In 2006, Hammer and Underdown presented the board with the scientific evidence refuting the validity of therapeutic touch as a legitimate treatment, but the board did not change its policy.
Sources: en.wikipedia.org
The four substrates of this enzyme are 4-aminobenzoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen and a proton. Its products are 4-aminophenol, oxidised NAD+, water, and carbon dioxide. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 4-aminobenzoate,NAD(P)H:oxygen oxidoreductase (1-hydroxylating, decarboxylating). Other names in common use include 4-aminobenzoate hydroxylase, and 4-aminobenzoate monooxygenase. It uses flavin adenine dinucleotide as a cofactor.
== Clinical applications == Several water-soluble derivatives and prodrugs of the widely used intravenous anesthetic agent propofol have been developed, of which fospropofol has been found to be the most suitable for clinical development thus far. Purported advantages of this water-soluble chemical compound include less pain at the site of intravenous administration, less potential for hyperlipidemia with long-term administration, and less chance for bacteremia. Often, fospropofol is administered in conjunction with an opioid such as fentanyl.
Poland is the largest producer of apples in Europe. Cider is known in Poland as Cydr or Jabłecznik. In 2013, Poles drank 2 million litres of cider, which adds up to 1% of the country's annual alcohol sales. Sales more than doubled from the previous year. In the summer of 2014, Minister of Economy Janusz Piechociński supported in vain the creation of a draft law to legalise television cider publicity. The category is just gaining popularity among consumers. Areas strong in cider production are focused around the centre of the country in the Masovian and Łódź voivodeships. Large quantities of Polish apple concentrate are exported to the European Union for cider production.
Hitler, aiming to use the crisis as a pretext for war, now demanded not only the annexation of the Sudetenland but also the immediate military occupation of Bohemia, Moravia and Slovakia, thus giving the Czechoslovak army no time to adapt its defence measures to the new borders. Hitler, in a speech at the Sportpalast in Berlin, claimed that the Sudetenland was "the last territorial demand I have to make in Europe" and gave Czechoslovakia a deadline of 28 September 1938 at 2:00 p.m. to cede the Sudetenland to Germany or face war. To achieve a solution, the Italian dictator, Benito Mussolini, suggested a conference of the major powers in Munich, and on 29 September, Hitler, Daladier and Chamberlain met and agreed to Mussolini's proposal (actually prepared by Hermann Göring) and signed the Munich Agreement. They accepted the immediate occupation of the Sudetenland. The Czechoslovak government, though not party to the talks, submitted to compulsion and promised to abide by the agreement on 30 September. The Sudetenland was assigned to Germany between 1 and 10 October 1938. The Czech part of Czechoslovakia was subsequently invaded by Germany in March 1939, with a portion being annexed and the remainder turned into the Protectorate of Bohemia and Moravia. The Slovak part declared its independence from Czechoslovakia and became the Slovak Republic (Slovak State), a satellite state allied to Germany.
44 (Rhodesia) Squadron, based in Lincolnshire on the east coast, was a heavy bomber unit, and part of No. 5 Group in RAF Bomber Command's front line. Unlike the other two squadrons designated as "Rhodesian", No. 44 Squadron never had a Rhodesian majority, despite efforts to so populate it. Initially equipped with Hampdens, it became the first RAF squadron to convert to Lancasters at the end of 1941. It played a prominent part in the attack on the MAN diesel factory at Augsburg in April 1942. In March 1943 No. 44 Squadron took part in the Allied bombing of cities in northern Italy, including Genoa and Milan, as well as targets in Germany such as Wilhelmshaven, Cologne and Berlin.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.